ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P ASX 200
7,576.70
0.09%
S&P ASX All Technology
2,973.00
0.14%
Brent Oil
83.565
0.03%
US Dollar vs AUD
1.53247
0.10%
Bitcoin
57,698.05
-0.93%
Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Mesoblast Limited (MESO)

  7. Mesoblast Limited (MESO) News

MESO

Mesoblast (MESO)

Mesoblast Limited
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:MESO
DateTimeSourceHeadlineSymbolCompany
30/04/202411:05GlobeNewswire Inc.Appendix 4c Quarterly Activity Report for Quarter Ended March 31, 2024NASDAQ:MESOMesoblast Limited
27/03/202400:25AllPennyStocks.comFDA Commentary Sends Biotech Soaring During Premarket HoursNASDAQ:MESOMesoblast Limited
26/03/202413:34GlobeNewswire Inc.United States Food & Drug Administration (FDA) Notifies Mesoblast that Available Clinical Data from Phase 3 Trial Appear Sufficient to Support BLA Submission for Remestemcel-L in Children with Steroid-Refractory Acute Graft Versus Host Disease (SR-aGVHD)NASDAQ:MESOMesoblast Limited
14/03/202410:30GlobeNewswire Inc.Mesoblast Successfully Completes Placement and Accelerated Entitlement OfferNASDAQ:MESOMesoblast Limited
11/03/202410:54GlobeNewswire Inc.United States Food & Drug Administration (FDA) Supports Accelerated Approval Pathway for Rexlemestrocel-L in End-Stage Heart Failure Patients with a Left Ventricular Assist Device (LVAD)NASDAQ:MESOMesoblast Limited
29/02/202409:57GlobeNewswire Inc.Mesoblast Reports Financial Results and Operational Update for Half-Year Ended December 31, 2023NASDAQ:MESOMesoblast Limited
26/02/202423:00GlobeNewswire Inc.Mesoblast Financial Results and Corporate Update WebcastNASDAQ:MESOMesoblast Limited
15/02/202411:46GlobeNewswire Inc.United States Food & Drug Administration (FDA) Grants Mesoblast Orphan-Drug Designation for Revascor® (Rexlemestrocel-L) in Children With Congenital Heart DiseaseNASDAQ:MESOMesoblast Limited
01/02/202413:34Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:MESOMesoblast Limited
31/01/202413:13GlobeNewswire Inc.Appendix 4C Quarterly Activity Report for Quarter Ended December 31, 2023NASDAQ:MESOMesoblast Limited
19/01/202411:28Dow Jones NewsMesoblast Gets FDA's Special Pediatric Designation for Revascor Heart TreatmentNASDAQ:MESOMesoblast Limited
19/01/202410:36GlobeNewswire Inc.United States Food & Drug Administration (FDA) Grants Mesoblast Rare Pediatric Disease Designation for Revascor® (Rexlemestrocel-L) in Children With Congenital Heart DiseaseNASDAQ:MESOMesoblast Limited
16/01/202422:33Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:MESOMesoblast Limited
05/01/202413:57Edgar (US Regulatory)Form F-6 POS - Post-effective amendments for immediately effective filingNASDAQ:MESOMesoblast Limited
23/12/202309:13Edgar (US Regulatory)Form F-6 POS - Post-effective amendments for immediately effective filingNASDAQ:MESOMesoblast Limited
27/11/202310:56GlobeNewswire Inc.Mesoblast Files for Orphan Drug and Pediatric Rare Disease Designations for Rexlemestrocel-L as Treatment for Severe Congenital Heart DiseaseNASDAQ:MESOMesoblast Limited
23/11/202305:35AllPennyStocks.comBiotech Shares Soar Following Major AnnouncementNASDAQ:MESOMesoblast Limited
23/11/202305:35AllPennyStocks.comBiotech Shares Soar Following Major AnnouncementNASDAQ:MESOMesoblast Limited
22/11/202310:32GlobeNewswire Inc.Mesoblast Partners With Blood and Marrow Transplant Clinical Trials Network (BMT CTN) on Pivotal Trial in Adults With SR-aGVHDNASDAQ:MESOMesoblast Limited
31/10/202311:04GlobeNewswire Inc.Appendix 4C Quarterly Activity Report for Quarter Ended September 30, 2023NASDAQ:MESOMesoblast Limited
26/09/202320:18GlobeNewswire Inc.Jane Bell AM Appointed Chair of Mesoblast Audit and Risk CommitteeNASDAQ:MESOMesoblast Limited
21/09/202317:30GlobeNewswire Inc.Key Outcomes From FDA Type A Meeting and Mesoblast Next Steps to Achieve RYONCIL ApprovalNASDAQ:MESOMesoblast Limited
06/09/202320:42Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:MESOMesoblast Limited
31/08/202309:07GlobeNewswire Inc.Mesoblast Reports Financial Results and Operational Update for Fiscal Year Ended June 30, 2023NASDAQ:MESOMesoblast Limited
29/08/202321:00GlobeNewswire Inc.Mesoblast Financial Results and Corporate Update WebcastNASDAQ:MESOMesoblast Limited
04/08/202323:03Dow Jones NewsMesoblast ADSs Plunge Premarket on Latest FDA RejectionNASDAQ:MESOMesoblast Limited
04/08/202310:10GlobeNewswire Inc.Mesoblast Receives Complete Response From U.S. Food and Drug Administration for Biologics License Application for Steroid-Refractory Acute Graft Versus Host Disease in ChildrenNASDAQ:MESOMesoblast Limited
31/07/202310:31GlobeNewswire Inc.Appendix 4C Quarterly Activity Report for Quarter Ended June 30, 2023NASDAQ:MESOMesoblast Limited
06/06/202322:46Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:MESOMesoblast Limited
05/06/202310:21GlobeNewswire Inc.Mesoblast Director Philip R. Krause, M.D., Appointed to Strategic Advisory RoleNASDAQ:MESOMesoblast Limited
 Showing the most relevant articles for your search:NASDAQ:MESO

Your Recent History

ASX
NAB
National Australia Bank
NYSE
MRK
Merck
ASX
XMM
S&P ASX 300 Metals and M...
FX
AUDJPY
AUD vs Yen
NYSE
VZ
Verizon Communications
ASX
WBC
Westpac Banking
CCOM
SILVER
SILVER
ASX
FMG
Fortescue
ASX
TLS
Telstra
ASX
WES
Wesfarmers
ASX
WPL
Woodside Petroleum
ASX
WOW
Woolworths
ASX
WDC
Westfield
ASX
NCM
Newcrest Mining
ASX
XTO
S&P ASX 100
NASDAQ
TSLA
Tesla
Delayed Upgrade Clock
ADVFN Logo

Australia
Company
Business
Popular
Get The App

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved